Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles.
about
Interventions for actinic keratosesMolecular cancer prevention: Current status and future directionsActinic keratosis: rationale and managementComprehensive management of actinic keratoses: practical integration of available therapies with a review of a newer treatment approach.Pharmacotherapy of actinic keratosis: an update.Actinic keratosis: update on field therapy.Skin permeation of small-molecule drugs, macromolecules, and nanoparticles mediated by a fractional carbon dioxide laser: the role of hair follicles.Impact of different vehicles for laser-assisted drug permeation via skin: full-surface versus fractional ablation.Safety, efficacy, and patient acceptability of imiquimod for topical treatment of actinic keratosesA network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in EuropeDevelopment of nanovesicular systems for dermal imiquimod delivery: physicochemical characterization and in vitro/in vivo evaluation.Cost-utility of first-line actinic keratosis treatments in FinlandMethods and Results Report - Evidence and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis -International League of Dermatological Societies in cooperation with the European Dermatology Forum.Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm MeetingNew developments in the treatment of actinic keratosis: focus on ingenol mebutate gel.A seamless phase I/II dose-finding trial assessing ingenol disoxate (LEO 43204) for field treatment of actinic keratosis on the scalp.Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.Optimal treatment of actinic keratoses.An Investigator-initiated Study to Assess the Safety and Efficacy of Imiquimod 3.75% Cream When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses on Dorsal Hands and Forearms.In-office Painless Aminolevulinic Acid Photodynamic Therapy: A Proof of Concept Study and Clinical Experience in More Than 100 PatientsEmerging drugs for actinic keratosis.Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses.An update on nonmelanoma skin cancer.Current and emerging treatment strategies for the treatment of actinic keratosis.Resiquimod, a topical drug for viral skin lesions and skin cancer.Update on non-melanoma skin cancer and the value of dermoscopy in its diagnosis and treatment monitoring.Pharmacotherapeutic management of actinic keratosis: focus on newer topical agents.Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers.Understanding efficacy end-points in studies of field-directed therapy for actinic keratosis.Medical approaches to non-melanoma skin cancer.Lmax and imiquimod 3.75%: the new standard in AK management.Ultraviolet radiation-induced non-melanoma skin cancer: Regulation of DNA damage repair and inflammationFormulation design for topical drug and nanoparticle treatment of skin disease.Adherence to topical therapies in actinic keratosis: A literature review.Use of Lesion Response Rate in Actinic Keratosis Trials.Treatment of Basal cell carcinoma with curettage followed by imiquimod 3.75% creamBritish Association of Dermatologists' guidelines for the care of patients with actinic keratosis 2017.Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology.Long-term sustained lesion clearance from Lmax with imiquimod 3.75%, a new field-directed treatment for actinic keratosis.Actinic keratosis: correlation between clinical and histological classification systems.
P2860
Q24202407-16749B75-EE8E-40B2-8309-72CB2761C685Q26797207-4A030F6F-1E87-4A47-B352-043ACBA482BDQ33785049-8637E88C-AB04-46E4-94F3-F483116BFF3EQ34299210-AF32A266-3C3D-42C4-9B11-D7BC0C15DC0CQ34378153-1B51FA10-66DE-42AC-8EAD-CE65BFE04246Q34441431-1640D46B-9AD8-4189-890B-F65196560E33Q34471349-DF52EC17-8F74-4396-8B45-13BD1218DBDAQ34983358-C9117AA4-3619-4C0C-82B6-1517B5902A65Q35044103-60B7DF1C-0160-4DEF-B265-85A6398D7105Q35180653-535D538A-2A4A-4CC0-9B3A-4A86DF07D310Q35635404-5E3B0739-629D-43EA-B7DA-D1EE3082AF64Q35666250-FB538AE8-E5D1-4D78-B00E-651DBD19959BQ35767304-C625A47E-9D38-4844-8B62-6F9B5987AD0EQ35822379-5080319C-B019-4D1C-869D-E128DE926E27Q36196699-1B53ABAE-39C6-48F1-AA66-2F53B296D971Q36247044-A1F3F426-C176-4C8C-9294-63038B8B45FAQ36373370-79147CEA-D8B4-4C7A-A1B5-0D1923E5C7B8Q36547571-68F70D96-9501-4582-9EFC-5B89EEA841A2Q36630030-7835E957-01A1-4100-A24A-3FA3A0504F0AQ36631465-AD674204-6EA7-48C7-987C-78A127E1A0F6Q37776509-CE8FFEE3-EB25-40AF-9BBE-8B4581BF449CQ37831354-CFCB391D-5F05-4C0B-82AC-E645F01B1E0AQ37851020-A0F30E54-81A2-4503-9A3A-7F5570F5A2A3Q37857684-C3AE8502-CD2C-4EF0-8BEB-99EFE7DA2B22Q38064483-B75A3930-C85D-4C12-921C-776CD872C507Q38101606-AE06443D-0C83-43C7-BEA6-E711D3563DC0Q38103795-EE7A5D6D-A1C5-4CC7-9A72-DF42AA915A2BQ38106805-FE8FFAA0-A957-4187-86CD-883CEB5E857CQ38130333-C03FF295-B960-41F0-A023-C55BD3BB25C3Q38162923-0BBA0E5D-CB81-4188-8A82-EF9A9020A4D8Q38282402-5CEC706B-48BE-4E47-A73A-E23C852F3D63Q38340621-8BD8D397-1C00-4CC4-BFF8-39FA716DA02CQ38358872-07D90059-98CE-4649-9045-386C5D8ADB50Q38830180-7DA56FB0-320E-4F5C-AC5A-B923D268E5A7Q42364289-F6A23081-E2A6-4620-9360-627A194CCCEAQ42488887-14EA2D11-B069-4A97-A3B2-FB211B6E4D6FQ48063272-82F6F5E6-9E65-4277-A3EB-9A483B5F576BQ50225349-53EED843-85CC-4453-B5E7-4DFA7331FE65Q52874179-F0606473-2EB1-4557-B763-510C849666F2Q53153798-10A68B6F-CD8E-4CBC-854A-F8EC4B035966
P2860
Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Imiquimod 2.5% and 3.75% for t ...... g scalp for two 2-week cycles.
@ast
Imiquimod 2.5% and 3.75% for t ...... g scalp for two 2-week cycles.
@en
Imiquimod 2.5% and 3.75% for t ...... g scalp for two 2-week cycles.
@nl
type
label
Imiquimod 2.5% and 3.75% for t ...... g scalp for two 2-week cycles.
@ast
Imiquimod 2.5% and 3.75% for t ...... g scalp for two 2-week cycles.
@en
Imiquimod 2.5% and 3.75% for t ...... g scalp for two 2-week cycles.
@nl
prefLabel
Imiquimod 2.5% and 3.75% for t ...... g scalp for two 2-week cycles.
@ast
Imiquimod 2.5% and 3.75% for t ...... g scalp for two 2-week cycles.
@en
Imiquimod 2.5% and 3.75% for t ...... g scalp for two 2-week cycles.
@nl
P2093
P1476
Imiquimod 2.5% and 3.75% for t ...... g scalp for two 2-week cycles.
@en
P2093
Brian Berman
Darrell S Rigel
James Kulp
Neil Swanson
Sharon Levy
William Abramovits
P304
P356
10.1016/J.JAAD.2009.07.004
P407
P577
2010-02-04T00:00:00Z